Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Receivables (2016 - 2025)

Marimed (MRMD) has disclosed Receivables for 14 consecutive years, with $9.4 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 7.54% to $9.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.4 million through Dec 2025, up 7.54% year-over-year, with the annual reading at $9.4 million for FY2025, 7.54% up from the prior year.
  • Receivables for Q4 2025 was $9.4 million at Marimed, up from $8.0 million in the prior quarter.
  • The five-year high for Receivables was $9.4 million in Q4 2025, with the low at $4.4 million in Q1 2023.
  • Average Receivables over 5 years is $7.4 million, with a median of $7.7 million recorded in 2024.
  • Peak annual rise in Receivables hit 181.12% in 2021, while the deepest fall reached 81.31% in 2021.
  • Over 5 years, Receivables stood at $6.7 million in 2021, then soared by 31.85% to $8.8 million in 2022, then decreased by 16.9% to $7.3 million in 2023, then grew by 19.69% to $8.7 million in 2024, then grew by 7.54% to $9.4 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $9.4 million, $8.0 million, and $7.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.